Jong Hwa Jun1, Young-Sik Yoo1, Sung A Lim1, Choun-Ki Joo2. 1. From the Department of Ophthalmology (Jun), Keimyung University School of Medicine, and Nune Eye Hospital (Lim), Daegu, the Catholic Institute for Visual Science (Yoo, Joo), and the Department of Ophthalmology and Visual Science (Joo), Seoul St. Mary's Hospital, College of Medicine, Catholic University of Korea, Seoul, South Korea. 2. From the Department of Ophthalmology (Jun), Keimyung University School of Medicine, and Nune Eye Hospital (Lim), Daegu, the Catholic Institute for Visual Science (Yoo, Joo), and the Department of Ophthalmology and Visual Science (Joo), Seoul St. Mary's Hospital, College of Medicine, Catholic University of Korea, Seoul, South Korea. Electronic address: ckjoo@catholic.ac.kr.
Abstract
PURPOSE: To determine the effects of topical 0.45% ketorolac tromethamine on intraoperative miosis and prostaglandin E2 (PGE2) release during femtosecond laser-assisted cataract surgery. SETTING: Seoul St. Mary's Hospital, Seoul, Korea. DESIGN: Prospective case series. METHODS: The study comprised the following 3 groups: conventional cataract surgery without topical NSAIDs (conventional group); femtosecond laser-assisted cataract surgery with preoperative topical ketorolac tromethamine 0.45% (femtosecond NSAID group), and femtosecond laser-assisted cataract surgery without topical NSAIDs (femtosecond no-NSAID group). To measure the aqueous humor PGE2 concentration, a 100 μL aqueous humor sample was collected from the anterior chamber after femtosecond laser pretreatment. The PGE2 concentration was measured using an enzyme immunoassay. RESULTS: Topical ketorolac tromethamine 0.45% led to a significant reduction in intraoperative miosis in the femtosecond NSAID group compared with the femtosecond no-NSAID group (P < .001). Absolute and relative reductions in pupil area in the femtosecond NSAID group were significantly lower than in the femtosecond no-NSAID group (P = .019 and P = .007, respectively). The mean aqueous humor PGE2 concentrations were 893.60 pg/mL ± 843.10 (SD) in the conventional group, 1911.43 ± 1178.63 pg/mL in the femtosecond NSAID group, and 743.63 ± 927.46 pg/mL in the femtosecond no-NSAID group (P < .001, conventional versus femtosecond NSAID and femtosecond NSAID versus femtosecond no NSAID; P > .05, conventional versus femtosecond NSAID). CONCLUSION: Preoperative topical ketorolac tromethamine 0.45% reduced miosis induced by femtosecond laser pretreatment and inhibited aqueous humor PGE2 elevation.
PURPOSE: To determine the effects of topical 0.45% ketorolac tromethamine on intraoperative miosis and prostaglandin E2 (PGE2) release during femtosecond laser-assisted cataract surgery. SETTING: Seoul St. Mary's Hospital, Seoul, Korea. DESIGN: Prospective case series. METHODS: The study comprised the following 3 groups: conventional cataract surgery without topical NSAIDs (conventional group); femtosecond laser-assisted cataract surgery with preoperative topical ketorolac tromethamine 0.45% (femtosecond NSAID group), and femtosecond laser-assisted cataract surgery without topical NSAIDs (femtosecond no-NSAID group). To measure the aqueous humor PGE2 concentration, a 100 μL aqueous humor sample was collected from the anterior chamber after femtosecond laser pretreatment. The PGE2 concentration was measured using an enzyme immunoassay. RESULTS: Topical ketorolac tromethamine 0.45% led to a significant reduction in intraoperative miosis in the femtosecond NSAID group compared with the femtosecond no-NSAID group (P < .001). Absolute and relative reductions in pupil area in the femtosecond NSAID group were significantly lower than in the femtosecond no-NSAID group (P = .019 and P = .007, respectively). The mean aqueous humor PGE2 concentrations were 893.60 pg/mL ± 843.10 (SD) in the conventional group, 1911.43 ± 1178.63 pg/mL in the femtosecond NSAID group, and 743.63 ± 927.46 pg/mL in the femtosecond no-NSAID group (P < .001, conventional versus femtosecond NSAID and femtosecond NSAID versus femtosecond no NSAID; P > .05, conventional versus femtosecond NSAID). CONCLUSION: Preoperative topical ketorolac tromethamine 0.45% reduced miosis induced by femtosecond laser pretreatment and inhibited aqueous humor PGE2 elevation.
Authors: Yu-Chi Liu; Melina Setiawan; Jia Ying Chin; Benjamin Wu; Hon Shing Ong; Ecosse Lamoureux; Jodhbir S Mehta Journal: Front Med (Lausanne) Date: 2021-12-17